ZA202208343B - Daptomycin formulation - Google Patents
Daptomycin formulationInfo
- Publication number
- ZA202208343B ZA202208343B ZA2022/08343A ZA202208343A ZA202208343B ZA 202208343 B ZA202208343 B ZA 202208343B ZA 2022/08343 A ZA2022/08343 A ZA 2022/08343A ZA 202208343 A ZA202208343 A ZA 202208343A ZA 202208343 B ZA202208343 B ZA 202208343B
- Authority
- ZA
- South Africa
- Prior art keywords
- daptomycin
- formulation
- solid
- daptomycin formulation
- present disclosure
- Prior art date
Links
- 108010013198 Daptomycin Proteins 0.000 title abstract 4
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 title abstract 4
- 229960005484 daptomycin Drugs 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000007787 solid Substances 0.000 abstract 3
- -1 aliphatic amino acid Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982945P | 2020-02-28 | 2020-02-28 | |
| PCT/EP2021/054841 WO2021170807A1 (en) | 2020-02-28 | 2021-02-26 | Daptomycin formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202208343B true ZA202208343B (en) | 2024-11-27 |
Family
ID=74797935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/08343A ZA202208343B (en) | 2020-02-28 | 2022-07-26 | Daptomycin formulation |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230068866A1 (enExample) |
| EP (1) | EP4110303A1 (enExample) |
| JP (2) | JP2023516957A (enExample) |
| CN (2) | CN118873500A (enExample) |
| AU (1) | AU2021227095B2 (enExample) |
| BR (1) | BR112022015571A2 (enExample) |
| CA (1) | CA3168727A1 (enExample) |
| MX (1) | MX2022010378A (enExample) |
| WO (1) | WO2021170807A1 (enExample) |
| ZA (1) | ZA202208343B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2770366C2 (ru) | 2017-08-31 | 2022-04-15 | Кселлия Фармасьютикалз Апс | Препараты даптомицина |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003055256A (ja) * | 2001-08-10 | 2003-02-26 | Nihon Pharmaceutical Co Ltd | 安定な血液凝固第xiii因子製剤 |
| RU2607526C2 (ru) | 2009-11-23 | 2017-01-10 | Кьюбист Фармасьютикалз ЭлЭлСи | Липопептидные композиции и родственные способы |
| RU2770366C2 (ru) * | 2017-08-31 | 2022-04-15 | Кселлия Фармасьютикалз Апс | Препараты даптомицина |
| GB201718888D0 (en) * | 2017-11-15 | 2017-12-27 | Ucb Biopharma Sprl | Method |
-
2021
- 2021-02-26 EP EP21708627.1A patent/EP4110303A1/en active Pending
- 2021-02-26 BR BR112022015571A patent/BR112022015571A2/pt unknown
- 2021-02-26 AU AU2021227095A patent/AU2021227095B2/en active Active
- 2021-02-26 US US17/794,734 patent/US20230068866A1/en active Pending
- 2021-02-26 CA CA3168727A patent/CA3168727A1/en active Pending
- 2021-02-26 CN CN202410944805.5A patent/CN118873500A/zh active Pending
- 2021-02-26 CN CN202180011662.7A patent/CN115038431B/zh active Active
- 2021-02-26 JP JP2022551653A patent/JP2023516957A/ja active Pending
- 2021-02-26 WO PCT/EP2021/054841 patent/WO2021170807A1/en not_active Ceased
- 2021-02-26 MX MX2022010378A patent/MX2022010378A/es unknown
-
2022
- 2022-07-26 ZA ZA2022/08343A patent/ZA202208343B/en unknown
-
2025
- 2025-07-18 JP JP2025120933A patent/JP2025142200A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118873500A (zh) | 2024-11-01 |
| US20230068866A1 (en) | 2023-03-02 |
| CA3168727A1 (en) | 2021-09-02 |
| BR112022015571A2 (pt) | 2022-09-27 |
| MX2022010378A (es) | 2022-09-21 |
| AU2021227095B2 (en) | 2024-02-22 |
| AU2021227095A1 (en) | 2022-08-25 |
| JP2025142200A (ja) | 2025-09-30 |
| JP2023516957A (ja) | 2023-04-21 |
| CN115038431B (zh) | 2024-08-09 |
| CN115038431A (zh) | 2022-09-09 |
| WO2021170807A1 (en) | 2021-09-02 |
| EP4110303A1 (en) | 2023-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015894A (es) | Peptidos acetales para estabilizar enzimas. | |
| PH12021551279A1 (en) | Modified amine lipids | |
| MX2023009645A (es) | Composiciones para preparar productos similares al huevo libres de animales. | |
| MX2014001372A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| ZA202309527B (en) | Ionizable lipids and compositions for nucleic acid delivery | |
| MX2022007275A (es) | Composiciones de acidos biliares y compuestos de fenilbutirato. | |
| MX2011012181A (es) | Composicion y metodo para controlar enfermedades de plantas. | |
| MX2011012334A (es) | Composicion y metodo para promover el crecimiento de raices de plantas. | |
| MX2021006126A (es) | Proceso de preparacion de una composicion tensioactiva a base de sal de ester de glicina betaina y composicion asi obtenida. | |
| ZA202208343B (en) | Daptomycin formulation | |
| MX2021006808A (es) | Novedosa psicosa-6-fosfato fosfatasa, composicion para la produccion de psicosa que comprende la misma y procedimiento para la produccion de psicosa mediante el uso de la misma. | |
| MX2019012454A (es) | Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol. | |
| PH12021551922A1 (en) | Afabicin formulation, method for making the same | |
| MX2025005727A (es) | Composiciones para el cuidado bucal | |
| MX2011012174A (es) | Composicion y metodo para controlar plagas. | |
| MX2018014966A (es) | Peptidos monolipidados resistentes a proteasas. | |
| MY207295A (en) | Method for preparing a composition comprising cetylated fatty acids | |
| MX392143B (es) | Composiciones cosméticas para el cuidado de la piel. | |
| MX2021011553A (es) | Producto para el cuidado bucal y metodos para uso y fabricacion de este. | |
| PH12022552789A1 (en) | Laminarin based formulation for agricultural applications | |
| PH12017502323A1 (en) | Novel xylanase | |
| MX2019006122A (es) | Metodo de hornear. | |
| MX370065B (es) | Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico. | |
| EA201692454A1 (ru) | Твердая фосфатная соль и способ ее получения | |
| PH12022550008A1 (en) | Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |